EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
News|Articles|September 18, 2026
FAQ: What the Endocrine Society’s New Scientific Statement Means for Obesity Treatment
Author(s)Sydney Jennings
Fact checked by: Abigail Brooks, MA
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Advertisement
Advertisement
Highly effective
Related to this article
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
A new scientific statement calls for a shift in obesity management and treatment to focus on overall health improvements rather than just weight loss alone.
Semaglutide brought 40.4% of children below the obesity BMI threshold, according to top-line results from the phase 3 STEP Young clinical trial.
US clinicians increasingly prescribe GLP-1 drugs to young children with obesity, although overall use remains limited and access disparities persist.
The FDA granted Breakthrough Device designation to Natera's cell-free DNA multi-cancer early detection assay. What it means for primary care.
Most adolescents with sporadic colorectal cancer present with stage III or IV disease, and few have a family history, per data presented at AAP 2026.
Freenome reports 18.2% sensitivity for advanced precancerous lesions and 80.4% for colorectal cancer with its updated blood screening test.
Advertisement
Advertisement